Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904501 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL1663130 | 0.80 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL30200200 | 0.80 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL4625651 | 0.79 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL2904519 | 0.78 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL30785121 | 0.78 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL1093645 | 0.78 | IDO1 (0.53) | ALDH1A1KDM4E | |
| SCHEMBL321697 | 0.78 | KDM4E (0.53) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 | |
| SCHEMBL31737743 | 0.78 | IDO1 (0.53) | ALDH1A1KDM4E | |
| SCHEMBL2908313 | 0.76 | PDE4A (0.50) | SLC6A2SLC6A4SLC6A3MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2223916-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | Eli Lilly and Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1682523-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7423037-B2 | e.g. 1-[1,1'-biphenyl]-2-yl-2-morpholin-2-ylpropan-2-ol; antidepressant, anxiolytic agent, cognition activator | ELI LILLY AND COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1729754-B1 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1729754-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1682523-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070083046-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885SLC6A3 3/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.